BiDil (isosorbide dinitrate and hydralazine): A new fixed-dose combination of two older medications for the treatment of heart failure in black patients

Cardiology in Review

Volumn 15, Issue 1, 2007, Pages 46-53

  Carmody, Melinda S ^a   Anderson, Joe R ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

African American; Congestive heart failure; Hydralazine; Isosorbide dinitrate

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDRALAZINE; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; ISOSORBIDE DINITRATE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; PRAZOSIN; SILDENAFIL;

AGE DISTRIBUTION; ANAMNESIS; ARTERY DILATATION; ARTERY MUSCLE; BLOOD FLOW; BLOOD PRESSURE; CARDIOVASCULAR RISK; CAUCASIAN; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COUGHING; DISEASE SEVERITY; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG UTILIZATION; ETHNICITY; EVIDENCE BASED PRACTICE; HEALTH CARE COST; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPOTENSION; MEDICARE; MORTALITY; NEGRO; NITROSYLATION; OXIDATION REDUCTION REACTION; PATIENT COMPLIANCE; QUALITY OF LIFE; RACE DIFFERENCE; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TABLET; TACHYCARDIA; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; VEIN DILATATION;

AFRICAN CONTINENTAL ANCESTRY GROUP; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; HYDRALAZINE; ISOSORBIDE DINITRATE; MALE; OXIDATION-REDUCTION; RETROSPECTIVE STUDIES;

EID: 33845736864     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.crd.0000250840.15645.fb     Document Type: Review

References (47)

1. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics - 2006 update a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:85-151.
2. Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J. 1997;133:703-712.
3. Dries DL, Exner DV, Gersh BJ, et al. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med. 1999;340:609-616.
4. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). American College of Cardiology web site. Available at: www.acc.org/clinical/guidelines/failure//index.pdf.
5. Pierpont GL, Cohn JN, Franciosa JA. Combined oral hydralazine-nitrate therapy in left ventricular failure: hemodynamic equivalency to sodium nitroprusside. Chest. 1978;73:8-13.
6. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314:1547-1552.
7. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303-310.
8. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-691.
9. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
10. Carson P, Ziesche S, Johnson G, et al, for the Vasodilator-Heart Failure Trial Study Group. Racial differences in response to therapy for heart failure: analysis of the Vasodilator-Heart Failure trials. J Card Fail. 1999;5:178-187.
11. Exner DV, Dries DL, Domanski MJ, et al. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med. 2001;344:1351-1357.
12. Weir MR, Gray JM, Paster R, et al. Differing mechanisms of action of angiotensin-converting-enzyme inhibition in black and white hypertensive patients. Hypertension. 1995;25:124-130.
13. Gillum RF. Pathophysiology of hypertension in blacks and whites: a review of the basis of racial blood pressure differences. Hypertension. 1979;1:468-475.
14. Kalinowski L, Dobrucki IT, Malinski T. Race-specific differences in endothelial function: predisposition of African Americans to vascular diseases. Circulation. 2004;109:2511-2517.
15. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87:840-844.
16. Malinski T. Understanding nitric oxide physiology in the heart: a nanomedical approach. Am J Cardiol. 2005;96(suppl):13i-24i.
17. Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest. 2005;115:500-508.
18. Murdoch CE, Grieve DJ, Cave AC, et al. NADPH oxidase and heart failure. Curr Opin Pharmacother. 2006;6:148-153.
19. Sydow K, Daiber A, Matthias O, et al. Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J Clin Invest. 2004;113:482-489.
20. Chen Z, Zhang J, Stamler JS. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci U S A. 99:8306-8311.
21. Lincoln TM, Dey N, Sellak H. Invited review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression. J Appl Physiol. 91:1421-1430.
22. Rinde-Hoffman D, Glasser SP, Arnett DK. Update on nitrate therapy. J Clin Pharmacol. 1991;31:697-701.
23. Bauer JA, Fung HL. Arterial versus venous metabolism of nitroglycerin to nitric oxide: a possible explanation of organic nitrate venoselectivity. J Cardiovasc Pharmacol. 1996;28:371-374.
24. Machado JD, Gomez JF, Bentacor G, et al. Hydralazine reduces the quantal size of secretory events by displacement of catecholamines from adrenomedullary chromaffin secretory vesicles. Circ Res. 2002;91:830-836.
25. Borges R, Machado D, Betancor G, et al. Pharmacological regulation of the late steps of exocytosis. Ann NY Acad Sci. 2002;971:184-192.
26. Munzel T, Kurz S, Rajagopalan S, et al. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of the membrane-bound NADH oxidase. A new action for an old drug. J Clin Invest. 1996;98:1465-1470.
27. Daiber A, Oelze M, Coldewey M, et al. Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure. Biochem Biophys Res Commun. 2005;338:1865-1874.
28. Denicola A, Radi R. Peroxynitrite and drug-dependent toxicity. Toxicology. 2005;208:273-288.
29. Stamler JS, Lamas S, Fang FC. Nitrosylation: the prototypic redox-based signaling mechanism. Cell. 2001;106:675-683.
30. Khan S, Lee KH, Minhas KM, et al. Neuronal nitric oxide synthase negatively regulates xanthine oxidoreductase inhibition of cardiac excitation-contraction coupling. Proc Natl Acad Sci U S A. 2004;101:15944-15948.
31. Hare JM. Nitroso-redox balance in the cardiovascular system. N Engl J Med. 2004;351:2112-2114.
32. Xu L, Eu JP, Meissner G, et al. Activation of the cardiac calcium release channel (ryanodine receptor) by poly-S-nitrosylation. Science. 1998;279:234-237.
33. Cappola TP, Kass DA, Nelson GS, et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation. 2001;104:2407-2411.
34. Damy T, Retajczak P, Shah AM, et al. Increased neuronal nitric oxide synthase-derived NO production in the failing human heart. Lancet. 2004;363:1365-1367.
35. Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol. 2004;555:589-606.
36. Gogia H, Anilkumar M, Parikh S, et al. Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. J Am Coll Cardiol. 1995;26:1575-1580.
37. Roland K, Nelson K, Kirsten D, et al. Clinical pharmacokinetics of vasodilators. Clin Pharmacokinet. 1998;35:9-36.
38. Chasseaud LF, Down WH, Grundy RK. Concentrations of the vasodilator isosorbide dinitrate and its metabolites in the blood of human subjects. Eur J Clin Pharmacol. 1975;8:157-160.
39. Evers J, Krakamp B, Klimkait W, et al. Pharmacokinetics of isosorbide-5-nitrate in renal failure. Eur J Clin Pharmacol. 1986;30:349-350.
40. Bauer H, Laufen H, Franz HE. Isosorbide dinitrate in plasma and dialysate during hemodialysis. Eur J Clin Pharmacol. 1986;30:187-190.
41. Vaccarino V, Gahbauer E, Kasl SV, et al. Differences between African Americans and whites in the outcome of heart failure: evidence for a greater functional decline in African Americans. Am Heart J. 2002;143:1058-1067.
42. Mulrow JP, Crawford MH. Clinical pharmacokinetics and therapeutic use of hydralazine in congestive heart failure. Clin Pharmacokinet. 1989;16:86-99.
43. Reece PA, Cozamanis I, Zacest R. Kinetics of hydralazine and its main metabolites in slow and fast acetylators. Clin Pharmacol Ther. 1980;28:769-778.
44. Isosorbide Dinitrate and Hydralazine Hydrochloride Tablets [package insert]. Lexington, MA: NitroMed Inc; 2005.
45. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049-2057.
46. Angus DC, Linde-Zwirble WT, Tam W, et al. Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure. Circulation. 2005;112:3745-3753.
47. Bloche MG. Race-based therapeutics. N Engl J Med. 2004;351:2035-2037.